{"id":"crushed-ticagrelor-followed-by-morphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a direct P2Y12 receptor antagonist that prevents adenosine diphosphate (ADP)-induced platelet activation and aggregation, reducing thrombotic events. Morphine is an opioid agonist that binds to mu receptors in the central nervous system to provide analgesia and anxiolysis. This combination is used in acute coronary syndromes to provide rapid antiplatelet effect (via crushed formulation for faster absorption) combined with pain management and sedation.","oneSentence":"Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:28.558Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with rapid antiplatelet and analgesic management"},{"name":"Acute myocardial infarction with pain control"}]},"trialDetails":[{"nctId":"NCT02939248","phase":"PHASE4","title":"Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2016-10","conditions":"Unstable Angina Pectoris","enrollment":30},{"nctId":"NCT02939235","phase":"PHASE4","title":"Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2016-07","conditions":"Unstable Angina Pectoris","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilique"],"phase":"marketed","status":"active","brandName":"Crushed ticagrelor followed by morphine","genericName":"Crushed ticagrelor followed by morphine","companyName":"Collegium Medicum w Bydgoszczy","companyId":"collegium-medicum-w-bydgoszczy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis. Used for Acute coronary syndrome with rapid antiplatelet and analgesic management, Acute myocardial infarction with pain control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}